Closing a Gap in Treating Chronic Condition Patients

Set to launch this summer, Uber Caregiver is tailored specifically for caregivers and their loved ones, aiming to tackle challenges head on and enhance the overall care experience.

This month's episode of the Meet the Board podcast features a new member of our editorial advisory board, Marci J. Chodroff, MD, FACP, vice president of Medical Affairs at Magellan Rx Management, a Prime Therapeutics company.

According to findings collected by Cedars-Sinai, artificial intelligence can reduce serious health risks associated with pregnancy and childbirth, and improve screening for some gynecological cancers.

The study found that the average annual costs for individuals with Chronic lymphocytic leukemia (CLL) were significantly higher compared to a matched non-CLL cohort.

To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year